ワクチン受託製造市場：タイプ、機能、用途別-2025年～2030年の世界予測

ワクチン受託製造市場の2023年の市場規模は50億6,000万米ドルで、2024年には55億1,000万米ドルに達すると予測され、CAGR 9.21％で成長し、2030年には93億9,000万米ドルに達すると予測されています。

ワクチン受託製造市場は主に、大規模生産、規制遵守、先進技術プラットフォームへの対応に特化した能力を有する第三者メーカーへのワクチン生産プロセスのアウトソーシングを伴う。この分野は、新たな感染症の出現や迅速なワクチン配備の必要性など、世界の健康課題が深刻化していることから、ますます重要性を増しています。ワクチン受託製造の必要性は、特にパンデミック（世界的大流行）の際に、スピードとキャパシティが重要なボトルネックとなるワクチン需要の高まりから生じています。アプリケーションは、感染症の予防ワクチン、腫瘍学、mRNA技術のような革新的な手法など、様々な治療分野に及んでいます。この分野のエンドユーザーは、主に製薬会社、ヘルスケアプロバイダー、政府機関などです。

市場の成長は、医薬品サプライチェーンの世界化、ワクチン製造法の技術進歩、ヘルスケア支出の増加など、いくつかの要因によって促進されます。さらに、疾病予防に関する意識の高まりや、風土病・パンデミックへの備えの重視も需要を後押ししています。ビジネスチャンスは、ヘルスケア・インフラや核酸ワクチンなど新規ワクチン技術に多額の投資を行っている新興市場にあります。バイオテクノロジー企業との提携を積極的に進め、柔軟な製造技術への投資を増やすことで、競争上の優位性が得られる可能性があります。しかし、厳しい規制環境、高額な初期資本投資、ワクチン製造における遺伝子組み換え生物に対する倫理的懸念といった課題は、成長を阻害する可能性があります。

自動化とバイオプロセスの革新への投資は、潜在的な成長分野です。さらに、コールドチェーン・ロジスティクスの改善やワクチンの有効性と安全性プロファイルの向上に関する調査も優先されるべきです。同市場は、急速な技術進歩と、総合力の活用を目指す企業間の提携によって特徴付けられます。潜在的な機会を捉えるため、企業は戦略的提携、能力を多様化するための水平展開、イノベーションを推進するための研究開発への重点投資に注力すべきです。従って、規制状況を理解し、各市場に合わせた事業を展開することが、このダイナミックな情勢下で持続的な成長を遂げ、競争上優位に立つためには不可欠です。

市場力学：急速に進化するワクチン受託製造市場における主要市場インサイトの解明

ワクチン受託製造市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 受託製造業者の生産能力拡大につながるワクチン需要の増加
  • 委託製造が提供するコストや時間の節約といった主な利点
  • 全世界におけるワクチン接種のカバー率
• 市場抑制要因
  • 老舗ワクチンメーカーによるアウトソーシングの制限
• 市場機会
  • 様々な年齢層の人口増加に対応するための世界の需要の高まり
  • 技術革新と強固なワクチンパイプライン
  • ワクチン製造のスピードアップに向けた政府の好意的な洞察とガイドライン
• 市場の課題
  • 製薬会社は戦略的コントロールを得るため、製造業務を内製化しています。

ポーターのファイブフォース：ワクチン受託製造市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ワクチン受託製造市場における外部からの影響の把握

外部マクロ環境要因は、ワクチン受託製造市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ワクチン受託製造市場における競合情勢の把握

ワクチン受託製造市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスワクチン受託製造市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ワクチン受託製造市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ワクチン受託製造市場における成功への道筋を描く

ワクチン受託製造市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ワクチンの需要増加により契約製造業者の生産能力が拡大
    • 契約サービスによって得られるコストと時間の節約などの主要な利点
    • 世界中のワクチン接種率
  • 抑制要因
    • 確立されたワクチン製造業者による限定的なアウトソーシング
  • 機会
    • 増加するさまざまな年齢層の人口に対応する世界の需要の高まり
    • イノベーションと強力なワクチンパイプライン
    • ワクチン製造を加速するための政府の好意的な見解とガイドライン
  • 課題
    • 製薬会社は戦略的コントロールを得るために自社で製造業務を行っている
• 市場セグメンテーション分析
  • タイプ：免疫力を高める弱毒化ワクチンの採用増加
  • 機能：バイオ製品の精製と配合を含む下流処理配合の使用の増加
  • 応用：感染症から人々を守るために人間が使用するワクチン受託製造の潜在能力の高まり
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ワクチン受託製造市場：タイプ別

• 弱毒化ワクチン
• DNAワクチン
• 不活化ワクチン
• サブユニットワクチン
• トキソイドワクチン

第7章 ワクチン受託製造市場：機能別

• 下流
  • 分析および品質管理研究
  • 充填および仕上げ作業
  • パッケージ
• 上流
  • 細菌発現システム
  • バキュロウイルスまたは昆虫発現システム
  • 哺乳類発現システム
  • 酵母発現システム

第8章 ワクチン受託製造市場：用途別

• 人間への使用
• 獣医

第9章 南北アメリカのワクチン受託製造市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋のワクチン受託製造市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのワクチン受託製造市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • VaxcyteとLonzaが、広域スペクトル肺炎球菌結合ワクチン（PCV）の世界の商業生産に向けた協力を拡大
  • オックスフォード、メリュー研究所からABL欧州を1,500万ユーロで買収
  • ファイザー、サムスンバイオロジクスと1億8,300万米ドルの契約製造契約を締結
• 戦略分析と提言

企業一覧

• AbbVie Inc
• Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc.
• Aton（Shanghai）Biotech Co., Ltd.
• Avid Bioservices, Inc.
• Catalent, Inc.
• Charles River Laboratories International, Inc.
• CSL Limited
• Curia Global, Inc.
• Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
• Emergent BioSolutions Inc.
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
• Gedeon Richter PLC
• GlaxoSmithKline PLC
• ICON PLC
• IDT Biologika GmbH
• KBI Biopharma, Inc. by JSR Corporation
• Klocke Pharma-Service GmbH
• Lonza Group Ltd.
• Merck KGaA
• Moderna, Inc.
• Pfizer Inc.
• Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
• Recipharm AB
• Serum Institute of India
• Vetter Pharma-Fertigung GmbH & Co. KG

LIST OF FIGURES

• FIGURE 1. VACCINE CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
• FIGURE 2. VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. VACCINE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. VACCINE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. VACCINE CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. VACCINE CONTRACT MANUFACTURING MARKET DYNAMICS
• TABLE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ATTENUATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL & QC STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL & FINISH OPERATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BACULOVIRUS OR INSECT EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY HUMAN USE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VETERINARY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 46. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 47. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 48. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 73. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 74. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 75. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 78. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 79. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 80. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 163. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 164. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 165. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 166. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. POLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. POLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 184. POLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 185. POLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 186. POLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. QATAR VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 188. QATAR VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 189. QATAR VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 190. QATAR VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 191. QATAR VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 237. VACCINE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 238. VACCINE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

The Vaccine Contract Manufacturing Market was valued at USD 5.06 billion in 2023, expected to reach USD 5.51 billion in 2024, and is projected to grow at a CAGR of 9.21%, to USD 9.39 billion by 2030.

The Vaccine Contract Manufacturing market primarily involves the outsourcing of vaccine production processes to third-party manufacturers who hold specialized capabilities in handling large-scale production, regulatory compliance, and advanced technology platforms. This sector is increasingly crucial due to escalating global health challenges, which include the emergence of new infectious diseases and the need for rapid vaccine deployment. The necessity of vaccine contract manufacturing arises from the growing demand for vaccines, especially during pandemics, where speed and capacity become critical bottlenecks. Applications span across various therapeutic areas including preventative vaccines for infectious diseases, oncology, and through innovative modalities like mRNA technology. End-users in this realm primarily include pharmaceutical companies, healthcare providers, and government agencies.

Market growth is propelled by several factors, including the globalization of pharmaceutical supply chains, technological advancements in vaccine production methods, and increasing healthcare expenditure. Moreover, the rise in awareness regarding disease prevention and the emphasis on endemic and pandemic preparedness also fuel demand. Opportunities lie in emerging markets that are investing heavily in healthcare infrastructure and in novel vaccine technologies such as nucleic acid vaccines. Venturing into partnerships with biotech firms and increasing investments in flexible manufacturing technology could provide competitive advantages. However, challenges such as stringent regulatory environments, high initial capital investments, and ethical concerns over genetically modified organisms in vaccine production can impede growth.

Investment in automation and bioprocessing innovations represents potential areas for growth. Additionally, research into improving cold chain logistics and enhancing vaccine efficacy and safety profiles should be prioritized. The market is typified by rapid technological advancements and partnerships between entities aiming to leverage collective strengths. To seize potential opportunities, firms should focus on strategic alliances, horizontal expansion to diversify capabilities, and heavy investment in R&D to propel innovation. Hence, understanding regulatory landscapes and tailoring operations for each market are vital for sustained growth and competitive advantage in this dynamic landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vaccine Contract Manufacturing Market

The Vaccine Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing demand for vaccines leading to capacity expansion by contract manufacturers
  • Key advantages such as cost and time saving offered by contract services
  • Vaccination coverage across the globe
• Market Restraints
  • Limited outsourcing by well-established vaccine manufacturers
• Market Opportunities
  • Rising global demand to cater to the growing population of varied age groups
  • Innovation and robust vaccine pipeline
  • Favorable government insights and guidelines to speed up the vaccine manufacturing
• Market Challenges
  • Pharma companies manufacturing operations in-house to gain strategic control

Porter's Five Forces: A Strategic Tool for Navigating the Vaccine Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vaccine Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vaccine Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vaccine Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vaccine Contract Manufacturing Market

A detailed market share analysis in the Vaccine Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vaccine Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vaccine Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vaccine Contract Manufacturing Market

A strategic analysis of the Vaccine Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vaccine Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc, Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc., Aton (Shanghai) Biotech Co., Ltd., Avid Bioservices, Inc., Catalent, Inc., Charles River Laboratories International, Inc., CSL Limited, Curia Global, Inc., Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Emergent BioSolutions Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation, Gedeon Richter PLC, GlaxoSmithKline PLC, ICON PLC, IDT Biologika GmbH, KBI Biopharma, Inc. by JSR Corporation, Klocke Pharma-Service GmbH, Lonza Group Ltd., Merck KGaA, Moderna, Inc., Pfizer Inc., Pharmaceutical Product Development by Thermo Fisher Scientific Inc., Recipharm AB, Serum Institute of India, and Vetter Pharma-Fertigung GmbH & Co. KG.

Market Segmentation & Coverage

This research report categorizes the Vaccine Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Attenuated Vaccine, DNA Vaccines, Inactivated Vaccine, Subunit Vaccines, and Toxoid Vaccines.
• Based on Function, market is studied across Downstream and Upstream. The Downstream is further studied across Analytical & QC studies, Fill & Finish Operations, and Packaging. The Upstream is further studied across Bacterial Expression Systems, Baculovirus or Insect Expression Systems, Mammalian Expression Systems, and Yeast Expression Systems.
• Based on Application, market is studied across Human Use and Veterinary.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing demand for vaccines leading to capacity expansion by contract manufacturers
    • 5.1.1.2. Key advantages such as cost and time saving offered by contract services
    • 5.1.1.3. Vaccination coverage across the globe
  • 5.1.2. Restraints
    • 5.1.2.1. Limited outsourcing by well-established vaccine manufacturers
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising global demand to cater to the growing population of varied age groups
    • 5.1.3.2. Innovation and robust vaccine pipeline
    • 5.1.3.3. Favorable government insights and guidelines to speed up the vaccine manufacturing
  • 5.1.4. Challenges
    • 5.1.4.1. Pharma companies manufacturing operations in-house to gain strategic control
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Growing adoption of attenuated vaccines to enhance immune systems
  • 5.2.2. Function: Increasing usage of downstream processing formulations that involve the purification and formulation of the bioproducts
  • 5.2.3. Application: Rising potential of vaccine contract manufacturing for human use to protect populations against infectious diseases
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Vaccine Contract Manufacturing Market, by Type

• 6.1. Introduction
• 6.2. Attenuated Vaccine
• 6.3. DNA Vaccines
• 6.4. Inactivated Vaccine
• 6.5. Subunit Vaccines
• 6.6. Toxoid Vaccines

7. Vaccine Contract Manufacturing Market, by Function

• 7.1. Introduction
• 7.2. Downstream
  • 7.2.1. Analytical & QC studies
  • 7.2.2. Fill & Finish Operations
  • 7.2.3. Packaging
• 7.3. Upstream
  • 7.3.1. Bacterial Expression Systems
  • 7.3.2. Baculovirus or Insect Expression Systems
  • 7.3.3. Mammalian Expression Systems
  • 7.3.4. Yeast Expression Systems

8. Vaccine Contract Manufacturing Market, by Application

• 8.1. Introduction
• 8.2. Human Use
• 8.3. Veterinary

9. Americas Vaccine Contract Manufacturing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Vaccine Contract Manufacturing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Vaccine Contract Manufacturing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
  • 12.3.2. Oxford Acquires ABL Europe From Institut Merieux For EUR 15 Mn
  • 12.3.3. Pfizer Inks USD 183M Contract Manufacturing Deal With Samsung Biologics
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc
• 2. Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc.
• 3. Aton (Shanghai) Biotech Co., Ltd.
• 4. Avid Bioservices, Inc.
• 5. Catalent, Inc.
• 6. Charles River Laboratories International, Inc.
• 7. CSL Limited
• 8. Curia Global, Inc.
• 9. Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
• 10. Emergent BioSolutions Inc.
• 11. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
• 12. Gedeon Richter PLC
• 13. GlaxoSmithKline PLC
• 14. ICON PLC
• 15. IDT Biologika GmbH
• 16. KBI Biopharma, Inc. by JSR Corporation
• 17. Klocke Pharma-Service GmbH
• 18. Lonza Group Ltd.
• 19. Merck KGaA
• 20. Moderna, Inc.
• 21. Pfizer Inc.
• 22. Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
• 23. Recipharm AB
• 24. Serum Institute of India
• 25. Vetter Pharma-Fertigung GmbH & Co. KG